Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDER Deputy Director Gerald Meyer

This article was originally published in The Tan Sheet

Executive Summary

Will retire from FDA on Jan. 30, 1994 after 20 years at the agency. Meyer, 57, has been the second-in-command at the Center for Drug Evaluation and Research since 1986 and has helped steer the center through its first years of reorganization, including several reconfigurations of drug review divisions. The deputy director also was involved in the overhaul of CDER's generic drugs division in the aftermath of the generics scandal and the elevation of OTCs and generics to office status. Other changes at CDER management may be just beyond the horizon; Center Director Carl Peck, MD, is understood to be reevaluating his career plans.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS081410

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel